Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XRTX | US
-0.17
-9.04%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.71
1.92
1.99
1.65
XORTX Therapeutics Inc. a late stage clinical pharmaceutical company engages in the development and commercialization of therapies to treat progressive kidney diseases diabetes insulin resistance metabolic syndrome diabetes diabetic nephropathy and infection. It develops XRx-008 a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101 an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225 a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation Inc. XORTX Therapeutics Inc. is based in Alberta Beach Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
196.1%1 month
154.6%3 months
295.4%6 months
217.7%-
0.96
2.02
0.03
0.02
0.09
-
-
-3.30M
5.15M
5.15M
-
-
-
-
-29.36
0.07
1.11
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.00
Range1M
1.01
Range3M
1.89
Rel. volume
0.42
Price X volume
90.40K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PALISADE BIO INC | PALI | Biotechnology | 3.91 | 5.41M | 0.51% | n/a | 5.06% |
ERNA | ERNA | Biotechnology | 0.9899 | 5.36M | -2.95% | n/a | -577.12% |
BIONOMICS LIMITED/FI | BNOX | Biotechnology | 0.2955 | 5.12M | -1.53% | n/a | 0.59% |
180 Life Sciences Corp | ATNF | Biotechnology | 4.97 | 5.10M | -1.19% | n/a | -105.81% |
Molecular Templates Inc | MTEM | Biotechnology | 0.75 | 4.94M | 0.00% | n/a | 155.07% |
QLGN | QLGN | Biotechnology | 0.1825 | 4.93M | 9.15% | n/a | -39.04% |
Enveric Biosciences Inc | ENVB | Biotechnology | 0.538 | 4.80M | 20.33% | n/a | 0.00% |
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.09 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 2.02 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 295.37 | 72.80 | Riskier |
Debt to Equity | 0.03 | -1.23 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 5.15M | 3.66B | Emerging |